Very Favorable Press Coverage Somewhat Likely to Impact Pacific Biosciences of California (PACB) Stock Price

Media coverage about Pacific Biosciences of California (NASDAQ:PACB) has been trending very positive this week, according to Accern. Accern identifies negative and positive press coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Pacific Biosciences of California earned a news sentiment score of 0.59 on Accern’s scale. Accern also gave news stories about the biotechnology company an impact score of 50 out of 100, meaning that recent press coverage is somewhat likely to have an impact on the company’s share price in the next several days.

Shares of Pacific Biosciences of California (NASDAQ PACB) opened at 3.44 on Monday. The firm’s market cap is $321.81 million. The firm has a 50-day moving average price of $3.60 and a 200-day moving average price of $4.48. Pacific Biosciences of California has a 12-month low of $3.11 and a 12-month high of $9.50.

Pacific Biosciences of California (NASDAQ:PACB) last announced its quarterly earnings results on Wednesday, April 26th. The biotechnology company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by $0.03. The business had revenue of $24.90 million for the quarter, compared to analyst estimates of $23.80 million. Pacific Biosciences of California had a negative return on equity of 87.51% and a negative net margin of 81.75%. Pacific Biosciences of California’s quarterly revenue was up 30.4% compared to the same quarter last year. During the same period last year, the firm earned ($0.23) EPS. Equities research analysts anticipate that Pacific Biosciences of California will post ($0.92) EPS for the current year.

A number of analysts have issued reports on PACB shares. Zacks Investment Research lowered Pacific Biosciences of California from a “hold” rating to a “sell” rating in a report on Thursday, March 23rd. Cantor Fitzgerald set a $8.00 target price on Pacific Biosciences of California and gave the company a “buy” rating in a report on Thursday, April 27th. Finally, ValuEngine lowered Pacific Biosciences of California from a “sell” rating to a “strong sell” rating in a report on Tuesday, June 13th.

ILLEGAL ACTIVITY NOTICE: “Very Favorable Press Coverage Somewhat Likely to Impact Pacific Biosciences of California (PACB) Stock Price” was reported by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this piece of content on another publication, it was copied illegally and republished in violation of US & international copyright legislation. The legal version of this piece of content can be accessed at https://sportsperspectives.com/2017/07/17/very-favorable-press-coverage-somewhat-likely-to-impact-pacific-biosciences-of-california-pacb-stock-price.html.

Pacific Biosciences of California Company Profile

Pacific Biosciences of California, Inc designs, develops and manufactures sequencing systems to help scientists resolve genetically complex problems. The Company is engaged in the development, manufacturing and marketing of an integrated platform for genetic analysis. Its Single Molecule, Real-Time (SMRT) technology enables single molecule, real-time detection of biological processes.

Insider Buying and Selling by Quarter for Pacific Biosciences of California (NASDAQ:PACB)

Receive News & Ratings for Pacific Biosciences of California Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacific Biosciences of California Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply